Small Cap Feast
Small Cap Feast – 17 April 2019
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 897
Total number of AIM Companies trading: 826*
* As at 12 April 2019
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 12 April 2019
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): 161*
Total number of Standard List Companies trading: 141*
* As at 12 April 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Rustranscom plc— specialised rail freight transportation in Russia and Kazakhstan, announced its potential intention to conduct an IPO of GDRs. The GDRs are expected to be admitted to the Official List of the FCA and to trading on the main market of the LSE. Offering is expected to comprise predominantly primary shares, in the amount of circa $300m.
Finablr plc— global platform which provides Cross-Border Payments and Consumer Solutions, Consumer Foreign Exchange Solutions and B2B and Payment Technology Solutions to consumers and businesses in the large and growing payments and foreign exchange market is looking to list on the Main Market plans to raise $200m
Main Market (Standard)
IMC Exploration Group (NEX: IMCP), focused on acquiring and exploring prospecting licence areas which have high potential for natural resource, is looking to admit its shares to the standard list and will withdraw for the NEX Exchange. Expected 11 June 2019
Techniplas –global producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient. FYDec17 rev $515m.
Loungers plc—the operator of 146 café/bar/restaurants across England and Wales under the Lounge and Cosy Club brands, announces its intention to seek admission on AIM, offer TBC, expected late April.
SDX Energy plc—a North Africa focused oil and gas company, announces its intention to complete a Canadian plan of arrangement under section 192 of the Canada Business Corporations Act and will have shares de-listed from the TSX-V and admitted to trading on AIM. Expected 28 May 2019, anticipated market cap of £76m
Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019.
Hurricane Energy (HUR.L) 45.6p £891.58m
Hurricane Energy, the UK based oil and gas company focused on hydrocarbon resources in naturally fractured basement reservoirs, announced that the 205/26b-C well (“Warwick Deep”) was spudded at 18:48 hrs on 16 April 2019 using the Transocean Leader rig.
Warwick Deep is the first in a three-well programme on Hurricane’s Lincoln and Warwick assets – the Greater Warwick Area (“GWA”). Hurricane has a 50% interest in the GWA following Spirit Energy’s farm-in to the P1368 South and P2294 licences in September 2018.
LiDCO (LID.L) 4.6p £11.11m
LiDCO, the hemodynamic monitoring company, announced that it has received regulatory approval for LiDCOrapid v3, the Company’s latest cardiac output monitor with non-invasive technology, for commercial sale in South Korea.
The Korean Ministry of Food and Drug Safety has formally approved the Company’s hemodynamic monitoring product for commercial sale in South Korea and it will be sold via LiDCO’s distribution partner Globaluck Ltd, a medical device sales group specialising in anesthesia and patient monitoring.
South Korea’s healthcare market is ranked fourth (by total medical device market size) among countries in the Asia-Pacific region. The country has an established hemodynamic monitoring market with local reimbursement already in place. LiDCO, via its distribution partner, will launch LiDCOrapidv3 at the 39th Annual Congress Korean Society of Critical Care Medicine.
Fusion Antibodies (FAB.L) 28.5p £6.3m
Fusion Antibodies, a pharmaceutical contract research organisation specialising in antibody engineering services, provides a business and unaudited trading update for year ended 31 March 2019, confirming the improvement in second half performance announced on 25 Feb 2019.
Significant increase in orders and revenues in H2 FY 2019
Capacity expansion completed on time and within budget
Rational Affinity Maturation Platform introduced in Dec 2018
Mammalian antibody library on track for delivery in FY 2020
Strong improvement in H2 revenues to £1.5m (H1 FY 2019: £0.7m, H2 FY 2018: £1.3m)
Revenues for the year ended 31 Mar 2019 expected to be £2.2m (2018: £2.7m)
Cash position at the year-end was £2m (31 March 2018: £4.5m)
Premier African Minerals (PREM.L) 0.07p £6.43m
Premier African Minerals announced that following the announcement on 14 Feb 2019, which outlined the proposed conditional acquisitions of 50% of KME Plant (Proprietary) Limited and 50% of the equity in Honey Badger Resources Limited, Premier will now not proceed with either transaction until there is some finality on the future of RHA Tungsten (Private) Limited (“RHA”). Accordingly, the proposed transactions with KME Plant Hire and HBR have been terminated today.
Premier notes that pursuant to our announcement on 13 March 2019, the final agreements are with the office of the Ministry of Industry, Commerce and Enterprise Development and Premier now awaits final sign-off.
Enteq (NTQ.L) 28.5p £15.65m
Enteq, the oilfield services technology and equipment supplier, announced an update for the financial year ended 31 Mar 2019.
The Board reported that trading has been stronger than anticipated in the period between the previous update issued on 20 Feb 2019 and the financial year end. Underlying EBITDA is now expected to be materially ahead of the Board’s previously upwards revised expectations. In addition to new business in North America, International sales have continued to grow. The Board expects to report revenue for the year ended 31 March 2019 of approximately $10m.
The cash balance as of 31 March 2019 was $11.9m, compared to $15.5m as at 31 March 2018 reflecting investments made in the rental fleet, engineering projects and product development.
Within the relative stable current market, the Board believes that this on-going investment strategy can result in further incremental opportunities.
Learning Technologies Group (LTG.L) 69.7p £440.2m
Learning Technologies Group, the leading integrated digital learning and talent management services and technologies provider, announced the acquisition of Breezy HR for initial cash consideration of $12m to be funded by the Group’s existing cash and bank facilities. The acquisition will support LTG’s strategic goal to achieve run-rate EBIT of at least £55m by the end of 2021.
Breezy is a fast-growing talent acquisition software business, providing small to medium sized businesses (SMB) with feature-rich, intuitive and user-friendly recruitment software to optimise their recruitment processes and maximise productivity. Breezy will become a business within PeopleFluent, part of LTG’s Software & Platforms division.
In the year ended 31 Dec 2018 Breezy reported unaudited revenue of $3.6m (2017: $1.3m) and EBIT grew to $0.28m (2017: $0.83m loss), reflecting the operational leverage of the business as it scales rapidly; 80% (2017: 67%) of Breezy’s revenue was derived from recurring subscription fees.
Directa Plus (DCTA.L) 62.5p £32.71m
Directa Plus, a producer and supplier of graphene-based products for use in consumer and industrial markets, announced its final results for the 12 months ended 31 Dec 2019.
Product and service sales revenue more than doubled to €2.25m (2017: €0.95m), total income (including grants) also more than doubled to €2.50m (2017: €1.23m)
Loss after tax €3.96m (2017: €3.95m)
Successful placing to raise £3.45m in Dec, with £1.32m received post period end
Cash and cash equivalents at year end of €5.5m (2017: €6.93m), increased by placing proceeds of €1.47m received in Jan 2019
Proven, successful strategy maintained
Target existing products and markets that can be significantly improved with the addition of Directa Plus products
Focus on those vertical markets in which the Company can gain strong traction – textiles, environmental, elastomers and composites
Altus Strategies (ALS.L) 3.8p £6.9m
Altus Strategies, the Africa focused project and royalty generator, announced that it has defined a further significant prospect at the Diba gold project. Diba is strategically located 13km south of the multi-million ounce Sadiola gold mine, in the world renowned ‘Kenieba Window’ gold belt in the west of the Republic of Mali.
Significant 650m x 400m new prospect discovered at Diba WNW from surface geochemistry
New prospect is contiguous to 1.85km long Diba NW target
Results highlight potential for multiple further target areas to be explored
Excellent historical drill intersections of 5.02g/t Au over 20.0m and 5.36 g/t over 13m
Diba hosts a historical near surface gold resource:
6,348,000 tonnes at 1.35 g/t for 275,200 ounces in the Indicated category
720,000 tonnes at 1.40 g/t for 32,500 ounces in the Inferred category
Based on a 0.5 g/t cut-off
Discussions continuing with a number of potential counterparties in respect of Diba
Universe Group (UNG.L) 5.47p £12.76m
Universe Group, a leading developer and supplier of point of sale, payment and loyalty systems, announced its audited results for the year ended 31 Dec 2018.
Results in line with Trading Update given in Sept 2018
Total revenues of £19.89m (2017: £19.62m)
Gross profit margin steady at 48.2% (2017: 47.6%)
Adjusted EBITDA £2.65m (2017: £2.37m)
Operating profit £0.91m (2017: £0.88m)
Profit after tax £0.80m (2017: £0.63m)
Statutory diluted EPS 0.33p (2017: 0.26p)
Net cash at year end £1.92m (31 Dec 2017: £1.86m)
Gempay 3 installed base now 2,930 devices
New customer wins for payment processing services e.g. Euro Garages
Launched partnerships with P97 and Ubamarket in the fields of mobile and in-car marketing and payment solutions and in-store scan-and-go applications
Absorbed impact and still grew revenues following the well-known demise of customer, Conviviality Plc, and the loss of a planned £2m point of sale installation
Post year-end on 3 April 2019, acquired Dublin based Camden Technology Investments Limited trading as Celtech, a class-leading developer of cloud-based retail and wholesale management solutions, for £4.96m
Amryt (TAM.L) 12.62p £34.01m
Amryt, a revenue-generating orphan drug company focused on acquiring, developing and commercialising products that help improve the lives of patients where there is a high unmet medical need, announced its preliminary unaudited results for the year ended 31 Dec 2018. It also provides a trading update for Q1 2019.
Revenues for 2018 amounted to €14.5m which represented a 13.3% increase on 2017 and this positive revenue momentum has continued into Q1 2019 with Lojuxta revenues growing by 28.1% compared to Q1 2018. This growth has been driven by the recent reimbursement decisions in the UK and France, with initial orders received from UK patients in Q4 2018 and from French patients in Q1 2019. Revenue growth has been further strengthened by a 118% increase in quarterly revenues from Saudi Arabia from Q4 2018 to Q1 2019.
The Company’s lead development asset, AP101, continues to progress, having recently successfully completed an unblinded interim efficacy analysis by an Independent Data Monitoring Committee of the Phase 3 EASE study in Epidermolysis Bullosa. The Committee recommended that the trial continue with a modest increase in the number of patients in the study, to 230 evaluable patients, to maintain 80% statistical power. The IDMC has also recently expanded the eligible patient population to include infants and children with EB between the ages of 21 days to 4 years of age. The Company also announced the commencement of its AP101 early access program for patients with EB in Colombia who are not eligible for the EASE study with the first shipments of product in late Q4 2018.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.